Skip to main content

ustekinumab (Stelara®)

 

Status: In progress

Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children.

  • Crohn’s disease: following loss of response or non-response to anti-TNF treatment.
  • ulcerative colitis: following loss of response or non-response to anti-TNF and vedolizumab

Patients started on anti-TNF would have been started after oral therapy, for example, azathioprine and/or be considered having severe disease and started on anti-TNF first line.

Medicine details

Medicine name ustekinumab (Stelara®)
Formulation infusion
Reference number OW25
Indication

As above

Company Janssen-Cilag Ltd
BNF chapter Gastro-intestinal system
Submission type One Wales
Status In progress
Date of issue TBA
Follow AWTTC: